MedImmune/Abbott Dispute Over Motavizumab Involves $50 Mil. In Synagis Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
MedImmune sues Abbott following its decision not to seek approval of the second-generation respiratory syncytial virus treatment outside the U.S.